We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+5.13%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.75B
AUM Growth
+$31.3M
Cap. Flow
+$37.1M
Cap. Flow %
2.11%
Top 10 Hldgs %
73.68%
Holding
42
New
–
Increased
21
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$18.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
3
UTHR icon
United Therapeutics
UTHR
+$13.5M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$12.3M
5
SAGE
Sage Therapeutics
SAGE
+$5.08M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$30.4M
2
ENDP
Endo International plc
ENDP
+$19M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.89M
4
TLPH icon
Talphera
TLPH
+$1.85M
5
ACGN
Aceragen Inc
ACGN
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 92.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$23.1B
$268M 15.29%
1,868,815
+105,357
+6% +$13.5M
ABMD
2
DELISTED
Abiomed Inc
ABMD
$214M 12.24%
1,903,584
+19,200
+1% +$2.22M
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$169M 9.64%
3,804,088
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.4B
$162M 9.26%
1,960,219
+169,320
+9% +$14.6M
AMAG
5
DELISTED
AMAG Pharmaceuticals
AMAG
$116M 6.64%
3,344,620
+17,900
+0.5% +$535K
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$87.3M 4.98%
713,742
+152,042
+27% +$18.6M
ZLTQ
7
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$74.9M 4.27%
1,720,763
+306,200
+22% +$12.3M
INSM icon
8
Insmed
INSM
$28.6B
$72.1M 4.11%
5,446,516
+355,218
+7% +$4.85M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$302M
$67M 3.82%
4,203,270
+92,562
+2% +$1.49M
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$59.9M 3.41%
2,604,593
+164,100
+7% +$3.82M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$51.6M 2.94%
1,009,930
+107,879
+12% +$5.08M
PRTA icon
12
Prothena Corp
PRTA
$450M
$48.9M 2.79%
993,855
+59,400
+6% +$3.28M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$5.03B
$44.2M 2.52%
1,532,030
+50,100
+3% +$1.33M
STAA icon
14
STAAR Surgical
STAA
$1.21B
$36.7M 2.1%
3,386,245
+141,635
+4% +$1.44M
EPZM
15
DELISTED
Epizyme, Inc
EPZM
$36.7M 2.1%
3,035,796
+221,256
+8% +$2.31M
CELG
16
DELISTED
Celgene Corp
CELG
$34.2M 1.95%
295,240
+2,540
+0.9% +$283K
ARIA
17
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$33.4M 1.9%
2,682,017
+94,400
+4% +$1.14M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$31.9M 1.82%
6,410,030
+724,642
+13% +$5.01M
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$30.1M 1.72%
213,360
+7,637
+4% +$1.03M
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$26M 1.48%
1,727,380
+76,504
+5% +$1.01M
GILD icon
21
Gilead Sciences
GILD
$165B
$22.8M 1.3%
318,400
– –
SHPG
22
DELISTED
Shire pic
SHPG
$21.1M 1.21%
124,100
+900
+0.7% +$160K
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$750M
$9.94M 0.57%
417,662
-100,947
-19% -$2.89M
AIMT
24
DELISTED
Aimmune Therapeutics
AIMT
$7.76M 0.44%
379,727
– –
EXAS
25
DELISTED
Exact Sciences
EXAS
$5.3M 0.3%
396,976
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q4 2016 Portfolio in Review

As of Q4 2016, Palo Alto Investors held 42 positions worth $1.75B, up 1.8% from $1.72B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q4 2016 filing shows 21 increased, 7 reduced and 4 closed positions. The largest sale was Cempra, Inc., an estimated $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier.

  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q4 2016, an estimated $18.6M increase.
  • Palo Alto Investors's biggest Q4 2016 reduction was Cempra, Inc., cutting an estimated $30.4M.
  • Palo Alto Investors fully exited Endo International plc in Q4 2016, selling an estimated $19M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $1.75B portfolio in Q4 2016.
  • Palo Alto Investors opened 0 new positions and closed 4 in Q4 2016.
  • Palo Alto Investors's portfolio value rose 1.8% quarter-over-quarter to $1.75B.

Based on Palo Alto Investors's 13F filing for Q4 2016, filed 15 Feb 2017.